[ABSTRAK
Latar Belakang : Sindrom frailty berkaitan dengan angka morbiditas dankematian yang lebih tinggi, sehingga dipakai sebagai prediktor kesehatan padaorang usia lanjut (usila). Polifarmasi sebagai salah satu faktor risiko sindromfrailty, dapat berkaitan dengan obat PPI yang sering diberikan pada usila, atasindikasi adanya keluhan gangguan saluran cerna bagian atas. Sampai saat inibelum ada penelitian yang mempelajari hubungan PPI jangka panjang dansindrom frailty pada usila. Penelitian ini diharapkan dapat memberikan datamengenai penggunaan PPI jangka panjang (≥ 6 bulan) terhadap risiko sindromfrailty pada usila.Metode : Desain studi kasus kontrol dengan kriteria inklusi subjek penelitian 60tahun ke atas dan berstatus kognitif baik. Kriteria ekslusi adalah data yg tidaklengkap atau terdapat kontraindikasi PPI. Kasus adalah usila terdiagnosis Frailtymenurut FI-40 item dan kontrol adalah usila yang tidak frailty berdasarkaninstrumen yang sama. Pengambilan data primer termasuk status frailty telahdilakukan bulan Maret-Juni 2013 oleh Seto E dan Sumantri S. Pengambilan datasekunder yang digunakan pada penelitian ini dilakukan pada bulan Oktober-November 2014 dari data primer tersebut, ditambah dengan data dari rekam medispoliklinik Geriatri dan poliklinik diabetes RS Cipto Mangunkusumo.Hasil : Didapatkan 225 subjek (75 kasus:150 kontrol), 59,6% berjenis kelaminperempuan (rerata usia 72,14 tahun; simpang baku ± 6,4 tathun) dan 47,1%berpendidikan tinggi. Subjek yang berpendidikan rendah, berstatus cerai mati,berstatus nutrisi lebih buruk, tidak mandiri, memerlukan caregiver, hidup tidakberkecukupan dan kondisi kesehatan yang lebih buruk lebih banyak didapatkanpada kelompok frailty dibandingkan kelompok yang tidak frail. Proporsipengguna PPI Jangka Panjang sebesar 40,9%. Penggunaan PPI jangka panjangmeningkatkan risiko sindrom frailty (Crude OR 2,15; IK 95% 1,22-3,78; p<0,007)dengan adjusted OR 1,83 (IK 1,0-3,36) terhadap variabel nutrisi dan merokok.Kesimpulan : Penggunaan PPI jangka panjang (≥ 6 bulan) secara independenmeningkatkan salah satu risiko sindrom frailty pada usila.

---

ABSTRACT
Background: Frailty syndrome as being used as the newest elderly healthpredictor, associated with higher morbidity and mortality. PPI are often used inelderly due to presence of upper gastrointestinal complaints, and related withpolypharmacy as one of the risk factor for frailty syndrome. No study has studiedthe relationship of long term PPI and frailty syndrome in elderly. The objective ofthe study is to find whether long term use of PPI (≥ 6 months) would increase therisk of frailty syndrome in the elderly.Methods: A case control study includes subjects 60 years and above with goodcognitive status. All subject with history of hypersensitivity of PPI is excluded.Elderly diagnosed as frailty based in FI-40 item is defined as cases, whileindividuals that are not frailty are classified as the control. Primary data(included frailty status) was collected on March-June 2013 by Seto E andSumantri S, et al. Secondary data used in the current study was gathered onOctober-November 2014, from the primary data above and from the medicalrecord taken from geriatric and diabetic outpatient clinics Cipto MangunkusumoHospital.Result: There were 225 subjects collected (75 cases : 150 controls), 59,6% werefemale (mean age 72,14 years old, SD ± 6,4 years) and 47,1% with highereducation. Lower education, divorced, poor nutrition, dependent, neededcaregiver, economicaly insufficient, more comorbidity and poor health conditionare seen in frailty group.The proportion of long term PPI use were 40,9%. Longterm PPI medication increase the risk of frailty syndrome (Crude OR 2,154; CI95% 1,225-3,778; p<0,007) with adjusted OR 1,83 (CI 95% 1,02-3,37) afteradjusting to nutrition and smoking variables.Conclusion: Long term use of PPI significantly increase the risk of frailtysyndrome compared to the non-users.;Background: Frailty syndrome as being used as the newest elderly healthpredictor, associated with higher morbidity and mortality. PPI are often used inelderly due to presence of upper gastrointestinal complaints, and related withpolypharmacy as one of the risk factor for frailty syndrome. No study has studiedthe relationship of long term PPI and frailty syndrome in elderly. The objective ofthe study is to find whether long term use of PPI (≥ 6 months) would increase therisk of frailty syndrome in the elderly.Methods: A case control study includes subjects 60 years and above with goodcognitive status. All subject with history of hypersensitivity of PPI is excluded.Elderly diagnosed as frailty based in FI-40 item is defined as cases, whileindividuals that are not frailty are classified as the control. Primary data(included frailty status) was collected on March-June 2013 by Seto E andSumantri S, et al. Secondary data used in the current study was gathered onOctober-November 2014, from the primary data above and from the medicalrecord taken from geriatric and diabetic outpatient clinics Cipto MangunkusumoHospital.Result: There were 225 subjects collected (75 cases : 150 controls), 59,6% werefemale (mean age 72,14 years old, SD ± 6,4 years) and 47,1% with highereducation. Lower education, divorced, poor nutrition, dependent, neededcaregiver, economicaly insufficient, more comorbidity and poor health conditionare seen in frailty group.The proportion of long term PPI use were 40,9%. Longterm PPI medication increase the risk of frailty syndrome (Crude OR 2,154; CI95% 1,225-3,778; p<0,007) with adjusted OR 1,83 (CI 95% 1,02-3,37) afteradjusting to nutrition and smoking variables.Conclusion: Long term use of PPI significantly increase the risk of frailtysyndrome compared to the non-users., Background: Frailty syndrome as being used as the newest elderly healthpredictor, associated with higher morbidity and mortality. PPI are often used inelderly due to presence of upper gastrointestinal complaints, and related withpolypharmacy as one of the risk factor for frailty syndrome. No study has studiedthe relationship of long term PPI and frailty syndrome in elderly. The objective ofthe study is to find whether long term use of PPI (≥ 6 months) would increase therisk of frailty syndrome in the elderly.Methods: A case control study includes subjects 60 years and above with goodcognitive status. All subject with history of hypersensitivity of PPI is excluded.Elderly diagnosed as frailty based in FI-40 item is defined as cases, whileindividuals that are not frailty are classified as the control. Primary data(included frailty status) was collected on March-June 2013 by Seto E andSumantri S, et al. Secondary data used in the current study was gathered onOctober-November 2014, from the primary data above and from the medicalrecord taken from geriatric and diabetic outpatient clinics Cipto MangunkusumoHospital.Result: There were 225 subjects collected (75 cases : 150 controls), 59,6% werefemale (mean age 72,14 years old, SD ± 6,4 years) and 47,1% with highereducation. Lower education, divorced, poor nutrition, dependent, neededcaregiver, economicaly insufficient, more comorbidity and poor health conditionare seen in frailty group.The proportion of long term PPI use were 40,9%. Longterm PPI medication increase the risk of frailty syndrome (Crude OR 2,154; CI95% 1,225-3,778; p<0,007) with adjusted OR 1,83 (CI 95% 1,02-3,37) afteradjusting to nutrition and smoking variables.Conclusion: Long term use of PPI significantly increase the risk of frailtysyndrome compared to the non-users.]